We are a global specialty pharmaceutical company based in Switzerland committed to development and commercialization of innovative medicines to meet the needs of patients living with rare diseases. The investor and media center features news and provides information and resources for investor and media communities.
At Santhera, we are passionate about providing treatment options for patients with rare diseases, specifically in the area of neuromuscular and pulmonary conditions - diseases that have a severe impact on the lives of affected children and adults. Our focus is on the development of treatments for neuromuscular and pulmonary diseases that currently lack treatment options.
At Santhera, we are passionate about providing treatment options for patients with rare diseases, specifically in the area of neuromuscular and pulmonary conditions - diseases that have a severe impact on the lives of affected children and adults. Our focus is on the development of treatments for neuromuscular and pulmonary diseases that currently lack treatment options.
Services
We are focusing on the development of treatments for neuromuscular and pulmonary diseases that currently lack treatment options, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). We have dedicated more than a decade to researching potential treatments in our ongoing mission to make effective medicines available for these often overlooked, life-altering diseases.
Santhera is a young and dynamic international pharma company, developing and commercializing innovative treatments for rare diseases. Our vision is to improve the lives of people with rare diseases, by delivering therapeutic options where none previously existed. Everything we do at Santhera, we do with respect.
As the disease progresses, the muscles affected include those needed for breathing (respiration), causing a problem called 'respiratory insufficiency' that leads to worsening breathing.
Parent Project Muscular Dystrophy (PPMD) - with support from Santhera Pharmaceuticals and input from a panel of parents, patients, and pulmonologists - has created a series of five short, informative animated videos to clarify, simplify, and teach important topics concerning pulmonary care.Video 1: Pulmonary management in DMD is important.
Parent Project Muscular Dystrophy (PPMD) - with support from Santhera Pharmaceuticals and input from a panel of parents, patients, and pulmonologists - has created a series of five short, informative animated videos to clarify, simplify, and teach important topics concerning pulmonary care.Video 1: Pulmonary management in DMD is important.
At Santhera, we have a set of core values that guide our decisions and actions every day: Commitment, Passion, Respect, Collaboration, and Accountability. And while we strive to infuse those values into all our efforts, nothing illustrates them greater than these stories of living with rare diseases.
This makes Raxone (idebenone 150 mg) the first and only medicine approved for this condition. In an interim phase, Santhera remains the EU marketing authorization holder and will continue to commercialize Raxone for LHON in France. The European Medicines Agency (EMA) has indicated that this medicine is subject to additional monitoring.
Reviews
Be the first to review Santhera Pharmaceuticals.
Write a Review
